Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
INBX compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name
INBX
Inhibrx Biosciences, Inc.
Change
Mkt cap
Revenue
Revenue
AMGN
Amgen Inc
Change
Mkt cap
Revenue
Revenue
vs
Compare
INBX
Inhibrx Biosciences, Inc.
vs
AMGN
Amgen Inc
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
INBX
0 of 4
at or beyond implied
Report
implied
realized
× implied
Q2 FY26
±11.9%
▼
−8.91%
×0.75
May 15 '26
±7.1%
▼
−6.47%
×0.92
Q1 FY26
±6.5%
▼
−6.09%
×0.94
Q3 FY25
±18.3%
▲
+6.04%
×0.33
AMGN
4 of 4
at or beyond implied
Report
implied
realized
× implied
Q3 FY26
±3.7%
▲
+3.73%
×1.00
Q2 FY26
±4.1%
▲
+4.57%
×1.12
= implied
INBX realized, solid
AMGN realized, hatched
One scale, both sides: full bar = 19%
× = |realized| ÷ implied
Source: market data
Q1 FY26
±3.9%
▼
−4.75%
×1.23
Feb 4 '26
±3.7%
▲
+8.15%
×2.22
INBX
Inhibrx Biosciences, Inc.
Change
84.59
▲
+5.37%
· post 84.60
Mkt cap
$1.2B
Revenue
$1M
Q2 FY25
Revenue
—
AMGN
Amgen Inc
Change
460.55
▲
+0.06%
· post 460.42
Closed
Nov 6 '26
Mkt cap
$249.0B
Revenue
$10.4B
Q3 FY26
Revenue
$36.8B
FY25
vs
Compare
Closed
Nov 6 '26
INBX
Inhibrx Biosciences, Inc.
vs
AMGN
Amgen Inc
84.59
▲
+5.37%
post 84.60
Price
460.55
▲
+0.06%
post 460.42
$1.2B
Mkt cap
$249.0B
Q2 FY25
$1M
Revenue
$10.4B
Q3 FY26
—
Revenue
$36.8B
FY25
Change
Change
INBX
84.59
▲
+5.37%
vs
AMGN
460.55
▲
+0.06%
Closed
Nov 6 '26